XNAS
BLTE
Market cap2.02bUSD
Jun 12, Last price
62.14USD
1D
1.70%
1Q
-7.87%
IPO
600.56%
Name
Belite Bio Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-32m
L+153.56%
CFO
-29m
L-2.02%
Profile
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 32,067 | 13,019 | |||
Unusual Expense (Income) | |||||
NOPBT | (32,067) | (13,019) | |||
NOPBT Margin | |||||
Operating Taxes | 9 | (173) | |||
Tax Rate | |||||
NOPAT | (32,076) | (12,846) | |||
Net income | (31,632) 153.56% | (12,475) 27.40% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 42,236 | 77,189 | 36,963 | ||
BB yield | -6.34% | -6.14% | |||
| Debt | |||||
Debt current | 276 | 308 | 198 | ||
Long-term debt | 798 | 1,464 | 1,534 | ||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (144,075) | (86,385) | (40,357) | ||
| Cash flow | |||||
Cash from operating activities | (29,234) | (29,837) | (11,458) | ||
CAPEX | (116) | (63) | (394) | ||
Cash from investing activities | (110,572) | (63) | (394) | ||
Cash from financing activities | 83,595 | 75,959 | 36,963 | ||
FCF | 336 | (31,999) | (14,130) | ||
| Balance | |||||
Cash | 145,149 | 88,157 | 42,089 | ||
Long term investments | |||||
Excess cash | 145,149 | 88,157 | 42,089 | ||
Stockholders' equity | (108,304) | (71,874) | (40,260) | ||
Invested Capital | 254,662 | 163,191 | 82,627 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 26,594 | 19,977 | |||
Price | 63.10 37.92% | 45.75 51.77% | 30.15 | ||
Market cap | 1,216,661 102.04% | 602,194 | |||
EV | 1,130,276 | 561,837 | |||
EBITDA | 449 | (31,668) | (12,821) | ||
EV/EBITDA | |||||
Interest | 25 | 16 | |||
Interest/NOPBT | |||||